Catecholaminergic neurones assessed ante-mortem in Alzheimer's disease
- PMID: 3620938
- DOI: 10.1016/0006-8993(87)90018-7
Catecholaminergic neurones assessed ante-mortem in Alzheimer's disease
Abstract
Indices of dopaminergic and noradrenergic varicosities were assayed in neocortical tissue obtained at diagnostic craniotomy from patients with Alzheimer's disease in the presenium. Dopaminergic markers (concentrations of dopamine, dihydroxyphenylacetic acid and homovanillic acid) were not significantly different from controls in either frontal or temporal cortex. In the frontal cortex, the release of endogenous dopamine and noradrenaline (in the presence of both resting and stimulating concentrations of potassium) was also unaffected whereas release of endogenous serotonin was significantly reduced. In the temporal cortex, noradrenergic markers (concentration of noradrenaline and uptake of radiolabelled noradrenaline) were significantly reduced, to at least 47% of mean control values. These deficits are interpreted as reflecting denervation and were present in patients examined only some two years after developing symptoms of dementia. The ratio of 3-methoxy-4-hydroxyphenylglycol to noradrenaline (a putative index of noradrenaline turnover) was elevated in the temporal cortex, suggesting increased activity of the remaining noradrenergic varicosities. Noradrenergic markers did not correlate with either clinical or histological indices of the severity of the disease which contrasts with presynaptic cholinergic and serotonergic markers.
Similar articles
-
Monoaminergic innervation of the frontal and temporal lobes in Alzheimer's disease.Brain Res. 1987 Jan 20;401(2):231-8. doi: 10.1016/0006-8993(87)91408-9. Brain Res. 1987. PMID: 2434191
-
Monoamine metabolism in senile dementia of Alzheimer type.J Neurol Sci. 1983 Aug-Sep;60(3):383-92. doi: 10.1016/0022-510x(83)90149-1. J Neurol Sci. 1983. PMID: 6195313
-
Changes in the brain catecholamines in patients with dementia of Alzheimer type.Br J Psychiatry. 1979 Sep;135:216-23. doi: 10.1192/bjp.135.3.216. Br J Psychiatry. 1979. PMID: 486847
-
Neurochemical studies of Alzheimer's disease.Neurodegeneration. 1996 Dec;5(4):381-91. doi: 10.1006/neur.1996.0051. Neurodegeneration. 1996. PMID: 9117551 Review.
-
Neurotransmitter deficits in Alzheimer's disease and in other dementing disorders.Hum Neurobiol. 1986;5(3):147-58. Hum Neurobiol. 1986. PMID: 2876973 Review.
Cited by
-
An experimental model of Braak's pretangle proposal for the origin of Alzheimer's disease: the role of locus coeruleus in early symptom development.Alzheimers Res Ther. 2019 Jul 3;11(1):59. doi: 10.1186/s13195-019-0511-2. Alzheimers Res Ther. 2019. PMID: 31266535 Free PMC article.
-
Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part I.Psychopharmacology (Berl). 1992;107(2-3):144-59. doi: 10.1007/BF02245132. Psychopharmacology (Berl). 1992. PMID: 1615119 Review.
-
Epigenetic dysregulation of brainstem nuclei in the pathogenesis of Alzheimer's disease: looking in the correct place at the right time?Cell Mol Life Sci. 2017 Feb;74(3):509-523. doi: 10.1007/s00018-016-2361-4. Epub 2016 Sep 14. Cell Mol Life Sci. 2017. PMID: 27628303 Free PMC article. Review.
-
A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment.Brain. 2022 Jun 30;145(6):1924-1938. doi: 10.1093/brain/awab452. Brain. 2022. PMID: 34919634 Free PMC article. Clinical Trial.
-
The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems.Neurochem Res. 1998 May;23(5):787-94. doi: 10.1023/a:1022419712453. Neurochem Res. 1998. PMID: 9566619 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical